Biogen announced that effective January 1, 2022, the company will cut the wholesale acquisition cost of the Alzheimer’s drug Aduhelm (aducanumab) in half.
Shares of Global Blood Therapeutics were up more than 10 percent in trading on December 17 following regulatory approval of a supplemental New Drug Application for oral Oxbryta (voxelotor) tablets for the treatment of pediatric sickle cell disease (SCD).
Eli Lilly and Company’s projections for next year exceed Wall Street projections for the drug manufacturer, predicting 2022 revenue of $27.8 billion to $28.3 billion.
Bristol Myers Squibb’s rheumatoid arthritis drug Orencia won marketing clearance as the first medicine approved for the prevention of moderate-to-severe acute graft versus host disease (aGvHD) in patients 2 years of age and older who have received unrelated donor hematopoietic stem cell transplantation.
Pfizer’s candidate treatment for patients diagnosed with active ankylosing spondylitis (AS) was approved by the U.S. Food and Drug Administration under a supplemental New Drug Application.
German researchers found that COVID-19 therapies developed by Eli Lilly and Regeneron lose most of their effectiveness when exposed in laboratory tests to the Omicron variant of coronavirus, likely reducing treatment options if the new variant prevails.
Molnupiravir – the main component in Merck and Ridgeback Therapeutics’ Covid-19 oral pill – might not be safe for use in pregnant women, according to the U.S. Food and Drug Administration.
The share price of Arena Pharmaceuticals nearly doubled in premarket trading after pharma giant Pfizer announced the acquisition of the company and its diverse portfolio of developmental and clinical assets – including a late-stage ulcerative colitis treatment – in an all-cash deal valued at $6.7 billion.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced Conditional Marketing Authorization (CMA) of RYBREVANT (amivantamab) for the treatment of adult patients with advanced NSCLC with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-based therapy.
Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on December 10 by the House Oversight Committee that highlighted Lilly, Novo Nordisk and Sanofi, which control the market for insulin.
